A clear link has been established between gastroduodenal disorders and Helicobacter pylori infection in humans. Of the many approaches taken to treat this disease, those utilizing H. pylori antigens with mucosal adjuvants like cholera toxin (CT-X) and mutant derivatives of heat-labile toxin of E. coli (LT) via the intragastric route figure prominently. Significant levels of protection have been obtained by prophylactic and to a lesser extent, therapeutic immunizations employing this strategy.
展开▼
